NCT07662408 Comparison of Norepinehrine Versus Phenylepherine Infusion for Prevention of Post-spinal Hypotension
| NCT ID | NCT07662408 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Sohag University |
| Condition | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2026-05-22 |
| Primary Completion | 2027-03-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 62 participants in total. It began in 2026-05-22 with a primary completion date of 2027-03-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized double-blinded clinical trial aims to compare the efficacy and hemodynamic effects of prophylactic norepinephrine infusion versus phenylephrine infusion for prevention of spinal anesthesia-induced hypotension in elderly patients undergoing elective orthopedic hip surgery under subarachnoid block. Sixty-two patients aged 60 years or older will be randomly assigned into two equal groups to receive either norepinephrine infusion (8 µg/min) or phenylephrine infusion (100 µg/min) immediately after spinal anesthesia. The primary outcome is the mean heart rate during vasopressor infusion, while secondary outcomes include incidence of hypotension, severe hypotension, bradycardia, reactive hypertension, intraoperative fluid requirements, blood loss, transfusion requirements, and postoperative nausea and vomiting. Hemodynamic parameters will be monitored throughout surgery to evaluate the safety and effectiveness of both vasopressor strategies.
Eligibility Criteria
Inclusion Criteria: 1. Age 60 years or older. 2. ASA physical status I-III. 3. Scheduled for elective hip surgery under subarachnoid block. 4. Willing to provide written informed consent. Exclusion Criteria: 1. Patient refusal. 2. Contraindications to subarachnoid block. 3. Severe cardiac disease. 4. Uncontrolled hypertension. 5. Allergy to study drugs. 6. Emergency surgery. 7. Monoamine oxidase inhibitor use. 8. Cognitive impairment preventing informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07662408 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 100 Years, studying Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07662408 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07662408 currently recruiting?
Yes, NCT07662408 is actively recruiting participants. Contact the research team at drahmedfaress23896@gmail.com for enrollment information.
Where is the NCT07662408 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT07662408 clinical trial?
NCT07662408 is sponsored by Sohag University. The trial plans to enroll 62 participants.